BioNTech SE: Pfizer and BioNTech Submit for U.S. Emergency U

Submission based on real-world safety and efficacy data from Israel Data showed rates of confirmed infections were 2 times lower and rates of severe illness were 4 times lower among individuals who received

Related Keywords

Germany , Qatar , Gilboa , Ha Afon , Israel , United States , Canada , United Kingdom , Israeli , Sylke Maas , Fosun Pharma , Emergency Department , Emergency Department Admission , Linkedin , Genentech , Twitter , United Kingdom Health Security Agency , Bayer Animal Health , Pfizer , Pfizer Inc , European Union , Facebook , Pfizer Inc Nasdaq , Drug Administration , Exchange Commission , Roche Group , Israeli Ministry Of Health , Large Us Health System , Emergency Use Authorization , Israeli Ministry , Kaiser Permanente Southern California , Marketing Authorization Holder , Emergency Use , Drug Administrationor , Prescribing Information , Caregivers Fact , Breakthroughs That Change Patient , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future , New Technologies , Private Securities Litigation Reform Act , Year Ended December , Dose Effectiveness , Associated Emergency Department , Urgent Care Encounters , Hospitalizations Among Adults During Periods , Omicron Variant Predominance , Mortal Wkly , Against Omicron Related Hospital , Kingdom Health Security , Efficacy Against Omicron , Biontech , Ubmit , Emergency , Authorization , Dditional , Rooster , Nose , Covid , Vaccine , Ilder , Adults ,